Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer
21 11월 2019 - 9:00PM
Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has
established a U.S. Headquarters in the Boston area and has hired
Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be
responsible for all investor relations, finance and administrative
functions, and will lead the Company’s future financing efforts to
support the company’s growth initiatives.
“We are pleased to have an accomplished
executive of Jon’s caliber join Entera Bio. We welcome his
long experience at emerging life science companies and his strong
investor and banking relationships,” stated Adam Gridley, CEO of
Entera. “As the company builds its presence with its
stakeholders, the addition of Jon as our U.S.-based CFO will be
critical to support our future growth, and our lead clinical
programs and in our business development efforts.”Jon’s background
includes financial and executive management roles at emerging and
growth-stage life science companies. As a CFO, he has raised
more than $300 million of equity and debt in public and private
securities offerings, including a $110 million IPO at Altus
Pharmaceuticals, and led strategic and business development
transactions including the successful sale of Xcellerex to GE
Healthcare. He currently serves as a managing director of Danforth
Advisors, and most recently served as CFO of Histogenics (NASDAQ:
HSGX), a publicly-traded cell therapy company developing products
for the orthopedics market. He additionally held the roles of
CFO for Metamark Genetics and CFO and Treasurer of Repligen.
Previously, Jon was an investment banker for ten years at Cowen and
Salomon Brothers, during which time he originated and executed on
numerous corporate financings and merger and acquisition
transactions. He received a BS in business administration and
finance from Boston University and an MBA in finance from New York
University Stern School of Business. The engagement terms of Mr.
Lieber are subject to the approval of the Company's
shareholders.Entera Bio Inc., the Company's wholly owned Delaware
subsidiary, established its U.S. Headquarters in the Boston area
(Wellesley, Mass) to support the Company’s future growth in
financial, business development and clinical / regulatory
staff. Centrally located near Boston’s biotechnology center
and New York’s banking center, the Company has a burgeoning
presence at both the board and executive level in important regions
for leading biotechnology companies. The Company’s R&D
operations will continue to be located in Jerusalem, Israel, where
much of the Company’s collaboration, clinical and CMC efforts will
expand to support our anticipated growth.
About Entera Bio Ltd.
Entera Bio is a clinical-stage biopharmaceutical
company focused on the development and commercialization of orally
delivered large molecule therapeutics for use in orphan indications
and other areas with significant unmet medical needs. The Company
is initially applying its technology to develop an oral formulation
of a human parathyroid hormone analog, Oral PTH (1-34), for
treatment of hypoparathyroidism and osteoporosis.
Entera has developed a proprietary platform
technology that enables oral delivery of biologicals and large
molecule drugs, which are typically delivered via injections and or
other non-oral pathways. However, oral drug delivery is the easiest
method for self-administering medications, offers patients greater
dosing flexibility, and has the highest patient acceptance and
compliance rates as compared to all other routes of drug
administration. The Company employs this technology for its own
pipeline products and may enter into licensing agreements with
biopharma companies for application of the technology to their
proprietary compounds, such as the Amgen strategic research
collaboration. For more information on Entera Bio,
visit www.enterabio.com.
Forward Looking StatementsThis
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "may," "should," "could," "would," "predicts,"
"potential," "continue," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates," and similar
expressions, as well as statements in future tense, often signify
forward-looking statements. Forward-looking statements should
not be read as a guarantee of future performance or results and may
not be accurate indications of when such performance or results
will be achieved. Forward-looking statements are based on
information that the Company has when those statements are made or
management's good faith belief as of that time with respect to
future events, and are subject to risks and uncertainties that
could cause actual performance or results to differ materially from
those expressed in or suggested by the forward-looking
statements. Those risks and uncertainties, include, but are
not limited to, the timing and conduct of our clinical trials, the
clinical utility of our product candidates, the timing and
likelihood of regulatory filings and approvals, our intellectual
property position, and our financial position. For a discussion of
these and other risks that could cause such differences and that
may affect the realization of forward-looking statements, please
refer to the "Special Note Regarding Forward-Looking Statements"
and "Risk Factors" in the Company's Annual Report on Form 20-F and
other filings with the Securities and Exchange Commission (SEC).
Investors and security holders are urged to read these
documents free of charge on the SEC's web site
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Entera Bio Ltd.
Adam Gridley, CEO
Tel: +972-2-532-7151
adam@enterabio.com
Histogenics (NASDAQ:HSGX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Histogenics (NASDAQ:HSGX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024